Lemborexant (E2006; E-2006; Dayvigo) is a novel, reversible, competitive and orally bioactive dual antagonist of the orexin OX1 and OX2 receptors (IC50 values of 6.1 nM and 2.6 nM, respectively) which was under development by Eisai for the treatment of insomnia. As of Dec 2019, Lemborexant was approved by FDA for the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance in adults.

纯度：≥98%

CAS：1369764-02-2